CSCO

Cisco and OECD Launch Pioneering Research Initiative on Digital Well-being

Retrieved on: 
Tuesday, January 16, 2024
Well, Knowledge, Senior, Research, World Forum, Sustainability, Life, Policy, Partnership, Housing, Mental health, Workplace, Work, CSCO, CDA, Statistics, Organization, Internet, Digital divide, Economy, Information Age, Education, Interface (computing)

DAVOS, Switzerland, Jan. 16, 2024 /PRNewswire/ -- Technology is transforming our lives, changing the way we learn, work, interact with others and get access to all types of services. Depending on our ability to access technology and use it in the right way, technology can improve our sense of well-being and be a real driver of progress. Cisco (NASDAQ: CSCO), a global technology leader committed to fostering an inclusive future for all, continues its efforts to address the digital divide through a new research collaboration with the Organisation for Economic Co-operation and Development (OECD).

Key Points: 
  • Cisco and the OECD WISE Centre will build a global knowledge hub for data and evidence on the influence of digital transformation on different aspects of people's lives and well-being.
  • Cisco (NASDAQ: CSCO), a global technology leader committed to fostering an inclusive future for all, continues its efforts to address the digital divide through a new research collaboration with the Organisation for Economic Co-operation and Development (OECD).
  • "The OECD has a long tradition of work supporting policy makers better understand the digital transformation and develop appropriate policies to help shape a positive digital future.
  • The partnership between Cisco and the OECD builds on existing research into digital well-being.

Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene

Retrieved on: 
Thursday, January 11, 2024
Neoplasm, Lasofoxifene, National Comprehensive Cancer Network, Patient, Incidence, Fulvestrant, AIS, Society, Breast cancer, Cancer, Breast, Eli Lilly, Mutation, CSCO, NCCN, Therapy, ESR1, Pharmaceutical industry

Under the terms of the agreement, Henlius will receive exclusive rights and sublicenses to lasofoxifene for at least two estrogen receptor-positive (ER+)/HER2- breast cancer indications in the territory, with Sermonix retaining all other global rights.

Key Points: 
  • Under the terms of the agreement, Henlius will receive exclusive rights and sublicenses to lasofoxifene for at least two estrogen receptor-positive (ER+)/HER2- breast cancer indications in the territory, with Sermonix retaining all other global rights.
  • Sermonix received an upfront payment and is further eligible to receive up to $58 million in certain predetermined milestones, in addition to royalties upon Henlius commercialization in China.
  • “In Phase 2 clinical trials, investigational lasofoxifene demonstrated its potential for the treatment of ER+/HER2- breast cancer harboring ESR1 mutation,” said Ping Cao, senior vice president and chief business development officer of Henlius.
  • “Lasofoxifene will play a critical role in complementing Henlius' pipeline of its breast cancer product.

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Retrieved on: 
Wednesday, January 10, 2024
Development, Oncology, Patient, Progression-free survival, OS, DCR, Survival, Dor, PD, Immunotherapy, RECIST, Aes, CSCO, Triple-negative breast cancer, PFS, Safety, HR, TNBC, ITT, Pharmaceutical industry

TORCHLIGHT is the first registered Phase 3 study to achieve positive results in advanced TNBC immunotherapy in China.

Key Points: 
  • TORCHLIGHT is the first registered Phase 3 study to achieve positive results in advanced TNBC immunotherapy in China.
  • A total of 300 patients had PD-L1-positive TNBC: 200 in the toripalimab arm and 100 in the control arm.
  • TORCHLIGHT’s results show that the addition of toripalimab to nab-paclitaxel significantly improved PFS for PD-L1-positive patients with metastatic or recurrent TNBC, while maintaining an acceptable safety profile.
  • The groundbreaking outcomes of this study has the potential to address unmet clinical needs and offer Chinese TNBC patients better treatment options.”

Cisco to Acquire Isovalent to Define the Future of Multicloud Networking and Security

Retrieved on: 
Thursday, December 21, 2023
Cloud, Policy, Ecosystem, Workload, Acquisition, Security, SAN, EBPF, Computation, Behavior, Knowledge, Engineering, CSCO, Organization, Communication, Environment, Network equipment provider

SAN JOSE, Calif., Dec. 21, 2023 /PRNewswire/ -- Cisco (NASDAQ: CSCO) today announced the intent to acquire Isovalent, a leader in open source cloud native networking and security, to bolster its secure networking capabilities across public clouds.

Key Points: 
  • Cisco intends to acquire privately held Isovalent, Inc., a leader in open source cloud native networking and security.
  • SAN JOSE, Calif., Dec. 21, 2023 /PRNewswire/ -- Cisco (NASDAQ: CSCO) today announced the intent to acquire Isovalent, a leader in open source cloud native networking and security, to bolster its secure networking capabilities across public clouds.
  • The acquisition of Isovalent will build on the Cisco Security Cloud vision, an AI-driven, cloud delivered, integrated security platform for organizations of any shape and size.
  • The Cisco Security Cloud enables customers to abstract security controls from multicloud infrastructure to provide advanced protection against emerging threats across any cloud, application or workload.

EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening

Retrieved on: 
Wednesday, December 20, 2023
Antibody, Epitope, EpiVax, CSCO, Partnership, Risk assessment, Phenotype, Dementia, Risk, Neurology, Vaccine

PROVIDENCE, R.I., Dec. 20, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has licensed EpiVax's ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai's robust biologics pipeline.

Key Points: 
  • PROVIDENCE, R.I., Dec. 20, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has licensed EpiVax's ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai's robust biologics pipeline.
  • "We're eager to enable Eisai with incorporation of rapid, secure, and advanced immunogenicity risk assessment"
    The ISPRI toolkit is a secure web-based platform that allows researchers to rapidly assess the immunogenic risk of biologic candidates.
  • Eisai's R&D organization plans to utilize the ISPRI toolkit to screen a wide range of therapeutic modalities, including antibodies, antibody-drug conjugates, and non-antibody protein therapeutics.
  • "We're eager to enable Eisai with incorporation of rapid, secure, and advanced immunogenicity risk assessment into their drug discovery process," said EpiVax CEO/CSO, Annie De Groot, MD.

Cisco Launches New Research, Highlighting Seismic Gap in Companies’ Preparedness for AI

Retrieved on: 
Tuesday, November 14, 2023
Motivation, Attention, Organization, Generative, Research, Policy, Risk, Artificial intelligence, Cisco, Culture, Element, Algorithm, Trust, Graphics processing unit, News, Bias, AI, Business, CSCO, Copper, Renewable energy, Medical device, Sales, Pacesetters, Index

The report highlights companies’ preparedness to utilize and deploy AI, showcasing critical gaps across key business pillars and infrastructures that pose serious risks for the near future.

Key Points: 
  • The report highlights companies’ preparedness to utilize and deploy AI, showcasing critical gaps across key business pillars and infrastructures that pose serious risks for the near future.
  • The findings show that companies experience the most challenges when it comes to leveraging AI alongside their data.
  • In fact, 83 per cent of respondents admit that this is due to data existing in silos across their organizations.
  • When it comes to building AI strategies, 95 per cent of organizations already have an AI strategy in place or in the process of developing one.

Splunk Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Transaction With Cisco

Retrieved on: 
Tuesday, November 14, 2023
Data Management, Technology, White House, Federal Government, Security, Other Technology, Apps, Applications, Software, Networks, Internet, Public Policy, Government, Mobile, Wireless, Splunk, Inc., Calendar, CSCO, Hart–Scott–Rodino Antitrust Improvements Act, Cryptocurrency, Pharmaceutical industry, Cisco

Splunk Inc. (NASDAQ: SPLK), the cybersecurity and observability leader, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”), in connection with the previously announced agreement for Splunk to be acquired by Cisco (NASDAQ: CSCO) for $157 per share in cash.

Key Points: 
  • Splunk Inc. (NASDAQ: SPLK), the cybersecurity and observability leader, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”), in connection with the previously announced agreement for Splunk to be acquired by Cisco (NASDAQ: CSCO) for $157 per share in cash.
  • The expiration of the waiting period under the HSR Act occurred at 11:59 p.m. Eastern Time on November 13, 2023.
  • The completion of the merger remains subject to the satisfaction of other closing conditions specified in the merger agreement, including approval of the merger under other applicable antitrust and foreign investment laws and approval by Splunk stockholders.
  • Splunk continues to expect to complete the merger by the end of the third calendar quarter of 2024.

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Retrieved on: 
Wednesday, December 6, 2023
NDA, Dexamethasone, Immunotherapy, NCCN, Disease, Hematology, Proteasome inhibitor, ESMO, Diagnosis, Multiple myeloma, International Myeloma Foundation, Patient, Guideline, Chinese, XPO1, Therapy, Selinexor, Oncology, Growth, CSCO, Pi, HIV disease progression rates, Pharmaceutical industry, Medical device

XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.

Key Points: 
  • XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
  • XPOVIO® is the world's first oral selective inhibitor of the nuclear export protein XPO1, with regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
  • "Antengene is excited to receive approval of XPOVIO® in Macau, first in the next wave of expected approvals in the APAC."
  • I am glad that XPOVIO® has become the first and only XPO1 inhibitor approved for the treatment of patients with R/R MM in Macau China.

Cisco Redefines Cybersecurity Defense with Powerful, Portfolio-Wide Artificial Intelligence Capabilities

Retrieved on: 
Tuesday, December 5, 2023
Cloud, Root cause analysis, Policy, Organization, CISCO, Privacy, Triage, Artificial intelligence, Talos, Cisco Talos, Intelligence, Human, Security, Firewall, AI, Responsibility, Telemetry, CSCO, Medical device, Cisco

MELBOURNE, Australia, Dec. 5, 2023 /PRNewswire/ -- CISCO LIVE -- Cisco (NASDAQ: CSCO), the leader in enterprise networking and security, today unveiled the Cisco AI Assistant for Security. This marks a major step in making artificial intelligence (AI) pervasive in the Security Cloud, Cisco's unified, AI-driven, cross-domain security platform. The AI Assistant will help customers make informed decisions, augment their tool capabilities and automate complex tasks.

Key Points: 
  • The new Cisco AI Assistant for Security marks a major step in making artificial intelligence pervasive in the Security Cloud, Cisco's unified, AI-driven, cross-domain security platform.
  • MELBOURNE, Australia, Dec. 5, 2023 /PRNewswire/ -- CISCO LIVE -- Cisco (NASDAQ: CSCO), the leader in enterprise networking and security, today unveiled the Cisco AI Assistant for Security.
  • This marks a major step in making artificial intelligence (AI) pervasive in the Security Cloud, Cisco's unified, AI-driven, cross-domain security platform.
  • The AI Assistant will help customers make informed decisions, augment their tool capabilities and automate complex tasks.

Cisco Doubles Down on Network Assurance with AWS

Retrieved on: 
Tuesday, November 28, 2023
Cloud, Senior, ThousandEyes, PM, Entrepreneurship, Amazon, Internet, Intelligence, Amazon CloudFront, PDT, Amazon Web Services, Lightning talk, IT network assurance, LAS, AWS, Lightning, CSCO, Network equipment provider, Television, Online shopping, Forging, Cisco

LAS VEGAS, Nov. 28, 2023 /PRNewswire/ -- AWS re:Invent -- Today at AWS re:Invent 2023, Cisco (NASDAQ: CSCO) announced new integrations between Cisco ThousandEyes and Amazon CloudWatch Internet Monitor (CWIM), a new Internet monitoring service from Amazon Web Services (AWS). The first-of-its-kind integration empowers customers with unparalleled visibility into their cloud deployments, enabling them to deliver unmatched optimized digital experiences.

Key Points: 
  • LAS VEGAS, Nov. 28, 2023 /PRNewswire/ -- AWS re:Invent -- Today at AWS re:Invent 2023, Cisco (NASDAQ: CSCO) announced new integrations between Cisco ThousandEyes and Amazon CloudWatch Internet Monitor (CWIM), a new Internet monitoring service from Amazon Web Services (AWS).
  • Building upon the existing relationship between AWS and Cisco , the new integration demonstrates Cisco's deep commitment to its end-to-end network assurance vision.
  • As the leader in Internet visibility, Cisco is on a mission to deliver unmatched, end-to-end network assurance.
  • — Mohit Lad, Senior Vice President and General Manager, Network Assurance, Cisco, and Co-Founder, ThousandEyes
    For more information and live demos visit ThousandEyes at AWS re:Invent at booth #1621.